Search Results

There are 4463 results for: content related to: Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer

  1. You have free access to this content
    In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

    British Journal of Clinical Pharmacology

    Volume 70, Issue 6, December 2010, Pages: 854–869, Landry K. Kamdem, Yong Liu, Vered Stearns, Susan A. Kadlubar, Jacqueline Ramirez, Stacie Jeter, Karineh Shahverdi, Bryan A. Ward, Evan Ogburn, Mark J. Ratain, David A. Flockhart and Zeruesenay Desta

    Version of Record online : 11 NOV 2010, DOI: 10.1111/j.1365-2125.2010.03791.x

  2. You have free access to this content
    Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

    Cancer

    Volume 92, Issue 9, 1 November 2001, Pages: 2247–2258, Jacques Bonneterre, Aman Buzdar, Jean-Marc A. Nabholtz, John F. R. Robertson, Bert Thürlimann, Mikael von Euler, Tarek Sahmoud, Alan Webster, Mark Steinberg and Arimidex Writing Committee on behalf of the Investigators Committee Members

    Version of Record online : 23 OCT 2001, DOI: 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y

  3. You have free access to this content
    A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

    Cancer

    Volume 79, Issue 4, 15 February 1997, Pages: 730–739, Aman U. Buzdar, Stephen E. Jones, Charles L. Vogel, Janet Wolter, Paul Plourde, Alan Webster and for the Arimidex Study Group

    Version of Record online : 27 SEP 2000, DOI: 10.1002/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0

  4. You have free access to this content
    Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor

    International Journal of Cancer

    Volume 133, Issue 7, 1 October 2013, Pages: 1589–1602, Paul Vilquin, Marie Villedieu, Evelyne Grisard, Sabrina Ben Larbi, Sandra E. Ghayad, Pierre-Etienne Heudel, Thomas Bachelot, Laura Corbo, Isabelle Treilleux, Julie A. Vendrell and Pascale A. Cohen

    Version of Record online : 2 MAY 2013, DOI: 10.1002/ijc.28182

  5. You have free access to this content
    Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

    Cancer

    Volume 101, Issue 6, 15 September 2004, Pages: 1311–1322, Bruce E. Hillner

    Version of Record online : 6 AUG 2004, DOI: 10.1002/cncr.20492

  6. You have free access to this content
    The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 51, Issue 5, May 2001, Pages: 429–435, R. A. Yates, J. Wong, M. Seiberling, M. Merz, W. März and M. Nauck

    Version of Record online : 12 JAN 2002, DOI: 10.1046/j.1365-2125.2001.01358.x

  7. Patterns of change in cognitive function with anastrozole therapy

    Cancer

    Volume 121, Issue 15, August 1, 2015, Pages: 2627–2636, Catherine M. Bender, John D. Merriman, Amanda L. Gentry, Gretchen M. Ahrendt, Sarah L. Berga, Adam M. Brufsky, Frances E. Casillo, Meredith M. Dailey, Kirk I. Erickson, Frances M. Kratofil, Priscilla F. McAuliffe, Margaret Q. Rosenzweig, Christopher M. Ryan and Susan M. Sereika

    Version of Record online : 23 APR 2015, DOI: 10.1002/cncr.29393

  8. You have free access to this content
    An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

    Cancer

    Volume 95, Issue 9, 1 November 2002, Pages: 2006–2016, Aman U. Buzdar, John F. R. Robertson, Wolfgang Eiermann and Jean-Marc Nabholtz

    Version of Record online : 25 OCT 2002, DOI: 10.1002/cncr.10908

  9. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226

    British Journal of Clinical Pharmacology

    Volume 81, Issue 6, June 2016, Pages: 1134–1141, Daniel L. Hertz, William E. Barlow, Kelley M. Kidwell, Kathy S. Albain, Ted A. Vandenberg, Shaker R. Dakhil, Nagendra R. Tirumali, Robert B. Livingston, Julie Gralow, Daniel F. Hayes, Gabriel N. Hortobagyi, Rita S. Mehta and James M. Rae

    Version of Record online : 8 APR 2016, DOI: 10.1111/bcp.12904

  10. You have full text access to this Open Access content
    Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen

    Cancer Science

    Volume 103, Issue 3, March 2012, Pages: 491–496, Yasuhiro Fujiwara, Yuichi Takatsuka, Shigeru Imoto, Hideo Inaji, Tadashi Ikeda, Futoshi Akiyama, Motoshi Tamura, Kazuya Miyoshi, Hiroji Iwata, Shoshu Mitsuyama and Shinzaburo Noguchi

    Version of Record online : 13 JAN 2012, DOI: 10.1111/j.1349-7006.2011.02171.x

  11. Hydrophilic interaction chromatography–electrospray ionization tandem mass spectrometric analysis of anastrozole in human plasma and its application to a pharmacokinetic study

    Biomedical Chromatography

    Volume 26, Issue 2, February 2012, Pages: 261–266, Hye Young Ji, Ji-Hong Sohn and Hye Suk Lee

    Version of Record online : 8 JUN 2011, DOI: 10.1002/bmc.1658

  12. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

    Intervention Review

    The Cochrane Library

    Lorna Gibson, David Lawrence, Claire Dawson and Judith Bliss

    Published Online : 7 OCT 2009, DOI: 10.1002/14651858.CD003370.pub3

  13. You have free access to this content
    Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer

    Cancer

    Volume 118, Issue 1, 1 January 2012, Pages: 241–247, Antonio Llombart-Cussac, Amparo Ruiz, Antonio Antón, Agustí Barnadas, Silvia Antolín, José E. Alés-Martínez, Isabel Álvarez, Raquel Andrés, José A. García Saenz, Juan Lao, Eva Carrasco, Carmen Cámara, Isabel Casas and Miguel Martín

    Version of Record online : 29 JUN 2011, DOI: 10.1002/cncr.26299

  14. Pre-treatment with anastrozole may be the optimal treatment sequence with radiotherapy for breast cancer

    Asia-Pacific Journal of Clinical Oncology

    Volume 4, Issue 1, March 2008, Pages: 27–33, Peter H GRAHAM, Zhi-Ming FANG and Raymond A CLARKE

    Version of Record online : 10 MAR 2008, DOI: 10.1111/j.1743-7563.2008.00144.x

  15. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor–positive early breast cancer. Analysis based on the ATAC trial

    International Journal of Gynecological Cancer

    Volume 16, Issue s2, September 2006, Pages: 576–578, K. MOEREMANS and L. ANNEMANS

    Version of Record online : 26 SEP 2006, DOI: 10.1111/j.1525-1438.2006.00699.x

  16. You have full text access to this OnlineOpen article
    A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer

    Cancer Science

    Volume 105, Issue 9, September 2014, Pages: 1182–1188, Ying Lin, Jianlun Liu, Xiaohua Zhang, Li Li, Rui Hu, Jian Liu, Yongchuan Deng, Dedian Chen, Yangbing Zhao, Shengrong Sun, Rong Ma, Ying Zhao, Jinping Liu, Yang Zhang, Xijing Wang, Yafen Li, Pingqing He, Enxiao Li, Zheli Xu, Yaqun Wu, Zhongsheng Tong, Xiaojia Wang, Tao Huang, Zhongxiao Liang, Shui Wang, Fengxi Su, Yunfei Lu, Helong Zhang, Guosheng Feng and Shenming Wang

    Version of Record online : 18 SEP 2014, DOI: 10.1111/cas.12474

  17. You have free access to this content
    Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

    Journal of Bone and Mineral Research

    Volume 21, Issue 8, August 2006, Pages: 1215–1223, Richard Eastell, Rosemary A Hannon, Jack Cuzick, Mitch Dowsett, Glen Clack and Judith E Adams

    Version of Record online : 22 MAY 2006, DOI: 10.1359/jbmr.060508

  18. Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view

    International Journal of Gynecological Cancer

    Volume 16, Issue s2, September 2006, Pages: 505–510, P. NEVEN, R. PARIDAENS, F. AMANT, H. WILDIERS, P. BERTELOOT, K. LEUNEN, A. SMEETS, C. WELTENS, W. Van Den BOGAERT, E. Van LIMBERGEN, M.R. CHRISTIAENS and I. VERGOTE

    Version of Record online : 26 SEP 2006, DOI: 10.1111/j.1525-1438.2006.00682.x

  19. Medical Therapies: Aromatase Inhibitors

    Endometriosis: Science and Practice

    Serdar E. Bulun, Erkut Attar, Bilgin Gurates, You-Hong Chen, Hideki Tokunaga, Diana Monsivais, Mary Ellen Pavone, Pages: 357–365, 2012

    Published Online : 25 JAN 2012, DOI: 10.1002/9781444398519.ch35

  20. You have free access to this content
    Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

    Cancer

    Volume 98, Issue 2, 15 July 2003, Pages: 229–238, John F. R. Robertson, C. Kent Osborne, Anthony Howell, Stephen E. Jones, Louis Mauriac, Matthew Ellis, Ulrich R. Kleeberg, Steven E. Come, Ignace Vergote, Stan Gertler, Aman Buzdar, Alan Webster and Charles Morris

    Version of Record online : 2 JUN 2003, DOI: 10.1002/cncr.11468